10月9日，梯瓦制药盘中上涨5.05%，报41.22美元/股，成交额9075.84万美元。
消息面上，美国FDA批准了该公司WELTRUZA用于成人精神分裂症治疗，该药为奥氮平长效皮下注射剂，每月一次给药，无需负荷剂量、口服补充或注射后监测，预计将在未来几周内在美上市。
此次批准基于其Solaris III期试验，数据显示疾病严重程度显著降低，个人与社会功能改善。此前，TD Cowen于10月1日对梯瓦制药给出买入评级，目标价55美元，反映市场对其创新管线和生物类似药商业化的持续关注。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.